(CNTG) Centogene V - Ratings and Ratios

Centogene N.V. (NASDAQ:CNTG) is a global leader in the field of rare and neurodegenerative diseases, offering a comprehensive suite of pharmaceutical solutions and diagnostic tests. With operations spanning Europe, the Middle East, North America, Latin America, and the Asia Pacific, the company delivers data-driven insights to patients, physicians, and pharmaceutical companies. Its cutting-edge solutions include CENTOGENE MOx 2.0, a multiomic testing platform that integrates DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based SaaS platform designed for genomic variant analysis; FilterTool, a genetic data interpretation tool; and CentoGenome, an NGS-based assay for diagnostic insights. Additionally, the company provides services such as target and drug screening, clinical development, market access, and patient recruitment, alongside its proprietary CENTOGENE Biodatabank for biomarker discovery and epidemiological research. Founded in 2006 and headquartered in Rostock, Germany, Centogene has established itself as a pioneer in genetic sequencing and diagnostics, offering whole exome, whole genome, and multiomic testing solutions to healthcare providers worldwide.

Based on the provided data, here is a 3-month forecast:

Average Volume 20d: 1834 | Last Price: 0.15 | SMA 20: 0.15 | SMA 50: 0.14 | SMA 200: 0.21 | ATR: 0.01

Market Cap: $9.43M | P/E: 0.00 | P/E Forward: 0.00 | P/B: 0.86 | P/S: 0.19 | RoE: 96.73

3-Month Forecast: The stock is expected to remain range-bound with limited upside potential due to low trading volume and volatility. The SMA 200 at 0.21 represents a potential resistance level, while the SMA 20 and SMA 50 suggest near-term stability. With a low ATR of 0.01, price fluctuations are likely to remain minimal. On the fundamental side, the low P/S ratio of 0.19 and P/B ratio of 0.86 indicate undervaluation, but the lack of P/E and forward P/E suggests earnings uncertainty. The high RoE of 96.73% may reflect leverage or operational efficiency, but without additional context, it remains a neutral factor. Overall, the stock is likely to trade sideways with potential for slight downward pressure due to its small market cap and limited liquidity.